Orchid Pharma merger update: key dates and swap ratio 2026

What Orchid Pharma disclosed to exchanges

Orchid Pharma Limited (OPL) has informed the NSE and BSE that its Scheme of Amalgamation with Dhanuka Laboratories Limited (DLL) has become effective from July 10, 2026. The disclosure was made under Regulation 30 of the SEBI Listing Regulations, in continuation of the company’s earlier intimation on the same date. OPL said the scheme became effective after completion of conditions specified under Clause 8 of the scheme. Following effectiveness, DLL stands dissolved without being wound up, as per the scheme terms. The company also shared operational actions linked to the scheme, including changes to its authorized share capital clause in the Memorandum of Association (MoA). In addition, OPL fixed a record date to determine which DLL shareholders will receive OPL shares.

Effective date, appointed date, and why both matter

The effective date of the amalgamation is July 10, 2026, which is when the scheme is stated to have become operative after required filings and completion of conditions. Separately, the appointed date for the scheme is April 1, 2024, which is relevant for accounting purposes. This distinction is common in court or tribunal-approved schemes where financial integration is considered from an earlier date. OPL reiterated both dates in its updates, indicating that while legal effectiveness is in July 2026, the accounting perspective begins from April 2024. For investors, the effective date is typically tied to corporate actions like dissolution of the transferor company and share allotment in the transferee company. The appointed date, meanwhile, influences how comparative financials and merger accounting may be presented.

NCLT Chennai sanction and the legal trigger

The National Company Law Tribunal (NCLT), Chennai Bench, sanctioned the scheme of amalgamation in an order pronounced on June 5, 2026. The scheme, filed under Sections 230 to 232 of the Companies Act, 2013, becomes effective upon filing the certified copy of the NCLT order with the Registrar of Companies (RoC). OPL’s exchange filing indicates that the scheme has now met the prescribed conditions and is effective as of July 10, 2026. Once effective, DLL ceases to exist as a separate entity and is dissolved without winding up. The company’s board meeting on July 10, 2026, also noted and approved consequential steps, including record date fixation and the revised MoA capital clause.

Authorized share capital revised to ₹164.51 crore

As part of the amalgamation, OPL said its authorized share capital has automatically increased due to the transfer and amalgamation of DLL’s authorized capital. The company stated that Clause V of its MoA now reflects an authorized share capital of ₹164.51 crore. This authorized capital is divided into 16,45,10,000 equity shares of face value ₹10 each. OPL’s disclosure frames this change as an automatic outcome of the scheme’s effectiveness rather than a separate discretionary action. For shareholders, the update clarifies the post-amalgamation capital headroom available for issuing shares under the approved swap ratio. It also provides a formal reference point for the capital structure as recorded in the MoA.

Record date set for July 23, 2026

OPL has fixed Thursday, July 23, 2026, as the record date to determine DLL shareholders eligible to receive shares in the amalgamated entity. The record date was set pursuant to Regulation 42 of the SEBI Listing Regulations and in consultation with DLL, according to the company’s filing. Record dates are a key operational milestone because they define entitlement for corporate actions. Investors in DLL needed to be on the register as of the record date to receive OPL shares under the scheme. OPL’s communication makes the timeline explicit, linking the effective date (July 10) to the subsequent entitlement date (July 23). The company has asked exchanges to take the intimation on record.

Share exchange ratio: 161 OPL shares for 5 DLL shares

The approved exchange ratio under the scheme is set at 161 fully paid-up equity shares of OPL for every 5 fully paid-up equity shares held in DLL. OPL shares issued under the scheme carry a face value of ₹10 each, while the DLL shares referenced in the ratio carry a face value of ₹100 each in the scheme wording. The disclosures also mention a face value sub-division for DLL shares from ₹100 to ₹10. This swap ratio is the central economic term of the amalgamation for DLL shareholders, as it defines how holdings convert into OPL equity. OPL has described the ratio as being pursuant to Para 16 of Part III of the scheme. The company’s record date announcement ties directly into executing this allotment.

Market datapoints cited alongside the corporate update

The information set provided includes market data for Orchid Pharma on the NSE, showing a current price of ₹1,002.25 and market capitalization of ₹5,083.32 crore at the referenced time. These figures were presented as snapshot values and not as part of the company’s board resolution. Separately, a preliminary placement document excerpt cited a floor price of ₹425.19 per equity share (calculated under Regulation 176 of the SEBI ICDR Regulations). The same excerpt stated that, as of that document date, 40,816,400 equity shares were issued, subscribed, and fully paid up, with a face value of ₹10 per share. It also referenced June 22, 2023 closing prices on BSE and NSE of ₹452.05 and ₹447.65, respectively. These datapoints provide context on trading and capital market references that appear in the overall material shared.

Other regulatory and operational context in the disclosures

The compilation of updates also referenced an order from the GST department demanding ₹1.67 crore plus interest relating to an allegedly erroneously sanctioned refund. Orchid Pharma has disputed this demand, stating it relates to the pre-CIRP period and is covered by the Resolution Plan, and has indicated plans to appeal. While separate from the amalgamation scheme, such items are typically tracked by investors because they can affect cash flows and compliance timelines. The corporate address and contact details of the company were also listed, including its registered office in Chennai and exchange identifiers (NSE symbol ORCHPHARMA and BSE scrip code 524372). The presence of these identifiers underscores that the amalgamation update was disseminated through formal exchange channels.

Key facts table

Why the update matters for shareholders

For OPL shareholders, the update confirms completion of a major corporate restructuring step and clarifies the post-scheme authorized capital. For DLL shareholders, the record date and swap ratio are the operational details that determine when and how equity entitlement is established. The scheme’s structure also reflects the standard sequencing of tribunal-sanctioned mergers in India: NCLT approval, RoC filing, scheme effectiveness, dissolution of the transferor entity, and share issuance based on a record date. The disclosures do not provide the final allotment date or listing timelines for the new shares, but they do confirm that the corporate prerequisites have been met for entitlement identification. The mention of a targeted revenue of ₹1,400 to ₹1,500 crore and EBITDA of ₹200 to ₹250 crore appears in the NCLT-related summary provided, indicating the financial ambition associated with the combined business, though the company’s exchange update focused on legal and capital steps. Investors typically track subsequent exchange filings for allotment confirmation and any updates on capital and shareholding changes.

Conclusion

Orchid Pharma has confirmed that its amalgamation with Dhanuka Laboratories is effective from July 10, 2026, with DLL dissolved without winding up and OPL’s authorized share capital revised to ₹164.51 crore. The company has also fixed July 23, 2026, as the record date for issuing shares under the 161:5 exchange ratio. The next set of disclosures investors are likely to watch for are procedural updates linked to share allotment to DLL shareholders and any further exchange communications tied to the scheme’s implementation steps.